BIOM30002 Study Guide - Final Guide: Amyloid, Beta-Secretase 1, Bapineuzumab

73 views2 pages
12 Jun 2018
Department
Course
Professor
Drug name
Drug class
Molecular
target
Mechanism
Issues/notes
trials
Semagacestat
(Eli Lilly)
Gamma
secretase
inhibitor
Gamma
secretase
Dose
-
dependently lower plasma, CSF and
brain Abeta in animals
Change both Abeta40/42 lv
D
id not slow AD
progression
Worsen cognition and motor ability
Due to non-selectivity (many substrates including NOTCH)
AE: increase risk of skin cancers and infections
III
Merck drug
MK-8931
(Verubecestat)
Beta
secretase
inhibitor/
Peptide-
based BACE1
inhibitor
Beta
secretase
Bind to BACE1 active site and inhibit
enzymatic activity
Low oral bio
-
a
va
ilability
Low serum half-life
Do not cross blood-brain barrier (BBB)
Difficult to make non-peptic BACE1 inhibitor that
1. large enough to bind to active site
2. but small enough to cross BBB and for PK properties
Knocking out both BACE1 & 2 is lethal
No clinical benefit
Suggesting worsening AD
II/III
AN1792
Active
(antigen)
anti-Abeta
vaccines
Abeta
Redu
ce amyloid plaques and Abeta lv
AN1792 is aggregated Abeta peptide
antigen
Ab need to cross the BBB
No significant improvement in mild-to-moderate AD
Interrupted due to meningoencephalitis due to T cell activation
No evidence of improved survival or improvement in time to
severe dementia
No effect on ND progression
IIa
Bapineuzumab
Passive
(antibody)
anti-Abeta
vaccines (3)
Abeta
1
-
5
Bapineuzumab is
humanized mAb to
epitope Abeta 1-5
Binds both soluble and fibrillar Abeta
Reduce amyloid burden in Tg mice
No effect in human
Phase III: failed in AD patients with/without ApoE4 allele
III
Solanezumab
Passive
(antibody)
anti-Abeta
vaccines (3)
Abeta16
-
24
Solanezumab is humanized mAb to
Abeta16-24
Preferentially binds to soluble Abeta
Reverse memory deficits without affecting
brain Abeta load in mice
Phase II: increase plasma and CSF
Abeta40/42, indicating reduction plaque
load in brain (reverse aggregation)
No effect on behavioral
(cognitive and functional) outcomes
Expedition III trial – changed protocol to now look at cognitive
performance as the main readout
Small treatment benefit and short of statistical significance
III
Stopped
Aducanumab
Passive
(antibody)
anti-Abeta
vaccines (3)
Abeta
3
-
7
mAb that targets linear epitope in Abeta
residue 3-7 in aggregated forms of beta
amyloid
Including soluble oligomers and insoluble
fibrils
Not powered to determine effects on cognition
1b
Unlock document

This preview shows half of the first page of the document.
Unlock all 2 pages and 3 million more documents.

Already have an account? Log in

Document Summary

Dose-depe(cid:374)de(cid:374)tl(cid:455) lo(cid:449)e(cid:396) plas(cid:373)a, csf a(cid:374)d (cid:271)(cid:396)ai(cid:374) a(cid:271)eta i(cid:374) a(cid:374)i(cid:373)als. Bi(cid:374)d to bace(cid:1005) a(cid:272)ti(cid:448)e site a(cid:374)d i(cid:374)hi(cid:271)it e(cid:374)z(cid:455)(cid:373)ati(cid:272) a(cid:272)ti(cid:448)it(cid:455) Bapi(cid:374)euzu(cid:373)a(cid:271) is hu(cid:373)a(cid:374)ized (cid:373)a(cid:271) to epitope a(cid:271)eta (cid:1005)-(cid:1009) Ae: i(cid:374)(cid:272)(cid:396)ease (cid:396)isk of ski(cid:374) (cid:272)a(cid:374)(cid:272)e(cid:396)s a(cid:374)d i(cid:374)fe(cid:272)tio(cid:374)s. Diffi(cid:272)ult to (cid:373)ake (cid:374)o(cid:374)-pepti(cid:272) bace(cid:1005) i(cid:374)hi(cid:271)ito(cid:396) that (cid:1005). la(cid:396)ge e(cid:374)ough to (cid:271)i(cid:374)d to a(cid:272)ti(cid:448)e site (cid:1006). (cid:271)ut s(cid:373)all e(cid:374)ough to (cid:272)(cid:396)oss bbb a(cid:374)d fo(cid:396) pk p(cid:396)ope(cid:396)ties. K(cid:374)o(cid:272)ki(cid:374)g out (cid:271)oth bace(cid:1005) & (cid:1006) is lethal. I(cid:374)te(cid:396)(cid:396)upted due to (cid:373)e(cid:374)i(cid:374)goe(cid:374)(cid:272)ephalitis due to t (cid:272)ell a(cid:272)ti(cid:448)atio(cid:374) No e(cid:448)ide(cid:374)(cid:272)e of i(cid:373)p(cid:396)o(cid:448)ed su(cid:396)(cid:448)i(cid:448)al o(cid:396) i(cid:373)p(cid:396)o(cid:448)e(cid:373)e(cid:374)t i(cid:374) ti(cid:373)e to se(cid:448)e(cid:396)e de(cid:373)e(cid:374)tia. Phase iii: failed i(cid:374) ad patie(cid:374)ts (cid:449)ith/(cid:449)ithout apoe(cid:1008) allele. Re(cid:448)e(cid:396)se (cid:373)e(cid:373)o(cid:396)(cid:455) defi(cid:272)its (cid:449)ithout affe(cid:272)ti(cid:374)g (cid:271)(cid:396)ai(cid:374) a(cid:271)eta load i(cid:374) (cid:373)i(cid:272)e. A(cid:271)eta(cid:1008)(cid:1004)/(cid:1008)(cid:1006), i(cid:374)di(cid:272)ati(cid:374)g (cid:396)edu(cid:272)tio(cid:374) pla(cid:395)ue load i(cid:374) (cid:271)(cid:396)ai(cid:374) (cid:894)(cid:396)e(cid:448)e(cid:396)se agg(cid:396)egatio(cid:374)(cid:895) (cid:373)a(cid:271) that ta(cid:396)gets li(cid:374)ea(cid:396) epitope i(cid:374) a(cid:271)eta (cid:396)esidue (cid:1007)-(cid:1011) i(cid:374) agg(cid:396)egated fo(cid:396)(cid:373)s of (cid:271)eta a(cid:373)(cid:455)loid. No effe(cid:272)t o(cid:374) (cid:271)eha(cid:448)io(cid:396)al (cid:894)(cid:272)og(cid:374)iti(cid:448)e a(cid:374)d fu(cid:374)(cid:272)tio(cid:374)al(cid:895) out(cid:272)o(cid:373)es. E(cid:454)peditio(cid:374) iii t(cid:396)ial (cid:272)ha(cid:374)ged p(cid:396)oto(cid:272)ol to (cid:374)o(cid:449) look at (cid:272)og(cid:374)iti(cid:448)e pe(cid:396)fo(cid:396)(cid:373)a(cid:374)(cid:272)e as the (cid:373)ai(cid:374) (cid:396)eadout.

Get access

Grade+20% off
$8 USD/m$10 USD/m
Billed $96 USD annually
Grade+
Homework Help
Study Guides
Textbook Solutions
Class Notes
Textbook Notes
Booster Class
40 Verified Answers